368 related articles for article (PubMed ID: 28166468)
21. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
Le Tourneau C; Razak AR; Gan HK; Pop S; Diéras V; Tresca P; Paoletti X
Eur J Cancer; 2011 Jul; 47(10):1468-75. PubMed ID: 21482105
[TBL] [Abstract][Full Text] [Related]
23. Determinants of the recommended phase 2 dose of molecular targeted agents.
Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
[TBL] [Abstract][Full Text] [Related]
24. Two-stage dose finding for cytostatic agents in phase I oncology trials.
Yin G; Zheng S; Xu J
Stat Med; 2013 Feb; 32(4):644-60. PubMed ID: 22855354
[TBL] [Abstract][Full Text] [Related]
25. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
26. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
[TBL] [Abstract][Full Text] [Related]
27. Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.
Huang B; Bycott P; Talukder E
J Biopharm Stat; 2017; 27(1):44-55. PubMed ID: 26882496
[TBL] [Abstract][Full Text] [Related]
28. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
29. Adaptive designs for identifying optimal biological dose for molecularly targeted agents.
Zang Y; Lee JJ; Yuan Y
Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of adaptive trial designs for dose optimization.
Zhang J; Chen X; Li B; Yan F
Pharm Stat; 2023; 22(5):797-814. PubMed ID: 37156731
[TBL] [Abstract][Full Text] [Related]
31. Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.
Yin J; Shen S
J Biom Biostat; 2016 Dec; 7(4):. PubMed ID: 28616356
[TBL] [Abstract][Full Text] [Related]
32. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
Lee SM; Wages NA; Goodman KA; Lockhart AC
JCO Precis Oncol; 2021 Jan; 5():317-324. PubMed ID: 34151131
[TBL] [Abstract][Full Text] [Related]
33. Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
Zang Y; Guo B; Qiu Y; Liu H; Opyrchal M; Lu X
Clin Trials; 2024 Jun; 21(3):298-307. PubMed ID: 38205644
[TBL] [Abstract][Full Text] [Related]
34. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
35. Dose escalation trial designs based on a molecularly targeted endpoint.
Hunsberger S; Rubinstein LV; Dancey J; Korn EL
Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
[TBL] [Abstract][Full Text] [Related]
36. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
37. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
38. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
39. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
[TBL] [Abstract][Full Text] [Related]
40. Optimal biological dose: a systematic review in cancer phase I clinical trials.
Fraisse J; Dinart D; Tosi D; Bellera C; Mollevi C
BMC Cancer; 2021 Jan; 21(1):60. PubMed ID: 33441097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
